6533b7d7fe1ef96bd1267a32
RESEARCH PRODUCT
The GERMELATOX DeCOG-trial : German melanoma patients and their attitude toward toxicity during adjuvant interferon treatment
Ralf GutzmerClaus GarbeChristine BlomePatrick TerheydenT. KornekDirk SchadendorfKatharina C. KaehlerChristoffer GebhardtBarbara StadeFlorian SchenckAxel HauschildBerenice M. RudolphMatthias AugustinTobias WagnerJochen UtikalAndrea ForschnerOzan AnguenElisabeth LivingstoneCarmen LoquaiPeter Mohrsubject
OncologyCancer Researchmedicine.medical_specialtybusiness.industryMelanomamedicine.medical_treatmentMedizinmedicine.diseaseOncologyInterferonInternal medicineToxicitymedicinebusinessneoplasmsAdjuvantmedicine.drugdescription
TPS9113^ Background: Although trials of adjuvant interferon alfa-2b (IFN alpha-2b) in high-risk melanoma patients suggest improvement in disease-free survival (DFS), a metaanalysis could only show ...
year | journal | country | edition | language |
---|---|---|---|---|
2014-05-20 |